Click HERE to download a PDF copy of the activity slides.
Welcome and Overview
A Practical Perspective on Advancements in Understanding of AD Pathophysiology
What’s Next in Diagnostic and Therapuetic Paradigms for AD? The Landscape of Clinical Trials
Question and Answer Session
Paul S. Aisen, MD
Professor, Department of Neurology
University of Southern California
Founding Director, Alzheimer’s Therapeutic Research Institute
Keck School of Medicine of USC
San Diego, California
Dennis J. Selkoe, MD
The Vincent and Stella Coats Professor of Neurologic Diseases,
Harvard Medical School
Co-Director, Center for Neurologic Diseases
Department of Neurology
Brigham and Women’s Hospital
The target audience for this educational activity is neurologists. Other healthcare professionals, including primary care physicians, geriatricians, and psychiatrists who care for patients with AD, may also benefit from participation in the proposed educational activities.
Alzheimer’s disease (AD) research is advancing at a fast pace in an effort to address its many diagnostic and treatment challenges. Diagnostic uncertainty results from complexities in patient history, inconsistency in examination results, and suboptimal use and/or incorrect application of neuroimaging techniques. Pathophysiological understanding and theory have evolved amid a growing body of evidence from basic and clinical research alike, and recent evidence of the mechanisms of Aβ deposition and propagation of tau may drive upcoming clinical advancements. Pharmacological treatment potential is limited because the vast majority of putative AD medicines do not receive clinical approval, and approved medications can only temporarily manage symptoms. Accordingly, the expert faculty, with lecture and medical illustration, will look ahead to the future of AD care with a focus on the evolving understanding of AD pathophysiology, the advances in diagnostic imaging, and the current status on the design and results of clinical trials of disease-modifying medications. The changing view of AD from a dementia to a chronic disease that progresses from a latent phase to mild cognitive impairment to functional impairment to dementia and the consequent implications in research and treatment will be at the core of each discussion.
As a result of participation in this educational activity, participants should be able to:
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Forefront Collaborative designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias.
This live activity is provided by Forefront Collaborative and is supported by an educational grant from Lilly.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Forefront Collaborative Complies with the Americans with Disabilities Act and will make every reasonable effort to accommodate your request.
This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs and devices.
The views and opinions expressed are those of the faculty and do not necessarily represent the views of Forefront Collaborative.